At the year’s start Thousand Oaks, CA-based Amgen closed a strategic collaboration with BeiGene, investing $2.8 billion to gain a presence in what’s becoming an ever-more essential market for global drug development. The investment earned it an R&D pact and ownership of about one-fifth of the Chinese oncology drug company. Now the firm has snapped … Continue reading “Amgen Doubles Down on BeiGene Collaboration, Investing $421M More”
Category: Boston
Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma
Rare disease drug developer Ovid Therapeutics is slated to reveal Phase 3 data from its lead program, a potential treatment for Angelman syndrome, by year’s end. If the drug is approved, the privately held Italian company Angelini Pharma will carry it forward for that indication in the Europe Union and a handful of other countries. … Continue reading “Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma”
Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More
Cash flowed throughout the life sciences ecosystem this week as Blackstone (NYSE: [[ticker:BX]]) raised a record-setting life sciences fund, companies of all stages announced new financings, and money continued to find its way to those working on efforts to treat or prevent COVID-19. Financiers poured $100 million or more into at least three biotechs, a … Continue reading “Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More”
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership
Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based company’s research into protein degradation, the natural mechanism cells use to get rid of unwanted proteins. Drug developers are eager to leverage that cellular recycling system to create new treatments because it … Continue reading “Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership”
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing
By early September Biogen—plus the many scientists, patients, and investors following the saga of its controversial Alzheimer’s drug aducanamab—should know whether the FDA plans to review the Cambridge, MA biotech’s experimental brain disease treatment. The company announced Wednesday that its submission to the FDA, pieces of which it has been submitting on a rolling basis, … Continue reading “Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing”
Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck
One way that a cell regulates which genes in its DNA are expressed and when is by altering the structure of the fibers that are formed by the genetic material and associated proteins, packaging that’s referred to as chromatin. Foghorn Therapeutics, which emerged in 2018 with plans to discover and develop new cancer drugs by … Continue reading “Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck”
Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine
The federal government’s Operation Warp Speed has made its biggest financing award yet, promising $1.6 billion to a Maryland biotech to help advance its investigational COVID-19 vaccine and ready millions of doses in preparation for its possible success. Gaithersburg, MD-based Novavax, which has never before brought a product to market, announced the federal award Tuesday. … Continue reading “Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine”
Cyteir Adds Chief Scientific Officer & Chief Business Officer to C-Suite
Cyteir Therapeutics, a developer of “synthetically lethal” drugs that tap into genetic interactions that lead to the death of cancer cells, has brought aboard two more top executives. The Lexington, MA-based company, which spun out of The Jackson Laboratory in 2012, added Paul Secrist as its chief scientific officer. Most recently Secrist was the senior … Continue reading “Cyteir Adds Chief Scientific Officer & Chief Business Officer to C-Suite”
Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs
Targeted therapies for treating cancer are designed to attack one or more proteins known to be on the surface of cancerous cells—but they don’t discriminate when they come across healthy cells expressing those same proteins. Vor Biopharma, an oncology company launched by Boston biotech PureTech Health in 2016, has raised $110 million in private financing … Continue reading “Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs”
PacBio CEO, CFO Plan Retirements and More People on the Move
Here’s a look back at some of the life science industry’s executive appointments, departures, and retirements from recent weeks: —Pacific Biosciences (NASDAQ: [[ticker:PACB]]) CEO Michael Hunkapiller and Chief Financial Officer Susan Barnes are retiring. —Moderna (NASDAQ: [[ticker:MRNA]]) appointed Ray Jordan as chief corporate affairs officer. —Aridis Pharmaceuticals (NASDAQ: [[ticker:ARDS]]) appointed Hasan Jafri its chief medical officer. … Continue reading “PacBio CEO, CFO Plan Retirements and More People on the Move”
On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO
The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating its intention to tap the public markets, too. The South San Francisco-based company has two clinical-stage product candidates, both of which are designed to … Continue reading “On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO”
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add multiple sclerosis and neuroinflammation to their ongoing partnership. The alliance came to New York-based Bristol (NYSE: [[ticker:BMY]]) via its acquisition of Celgene last year. The original 2017 deal covered the development of … Continue reading “Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases”
Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients
Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean taking concerted steps to reach out to populations that can be harder to recruit for clinical trials, drug industry leaders said on a recent New York Academy of Sciences webinar. Moderna … Continue reading “Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients”
BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity
[Updated 7/2/2020, 9:27 a.m. See below.] A BioNTech messenger RNA vaccine candidate for COVID-19 has shown in a small study that it can elicit an immune response to the novel coronavirus. The 45-patient US study tested three doses of the experimental mRNA vaccine, BNT162b1, along with a placebo. Early results now available show higher levels … Continue reading “BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity”
Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s
[Updated, 4:54 p.m.] Amylyx Pharmaceuticals’ two-pronged approach to neurodegenerative diseases has shown promise in amyotrophic lateral sclerosis (ALS) testing and the company now has $30 million to complete a separate clinical trial in Alzheimer’s disease. The Series B round of financing announced Wednesday was led by Morningside Ventures, a firm that had previously invested in … Continue reading “Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s”
Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases
The blood-brain barrier protects the functioning of that essential organ, but it’s also a hurdle to delivering neurological drugs. Italy’s Chiesi Group has agreed to pay Guilford, CT-based Bioasis Technologies $3 million up front to use the preclinical firm’s technology to facilitate the delivery of enzymes across the blood-brain barrier to treat neurological symptoms associated … Continue reading “Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases”
Akcea Therapeutics Names Tracy Palmer Berns Chief Compliance Officer
Tracy Palmer Berns has joined rare disease drug developer Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) as chief compliance officer, the same role she held most recently at AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]). Her experience also includes compliance and regulatory positions at Medtronic (NYSE: [[ticker:MDT]]) and Covidien, which Medtronic acquired in 2015. Boston-based Akcea has two commercialized products: hereditary … Continue reading “Akcea Therapeutics Names Tracy Palmer Berns Chief Compliance Officer”
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
Goldfinch Bio, a biotech company employing genetic analysis to develop new medicines for kidney diseases, has raised $100 million to bring its lead drug candidate into mid-stage clinical trials. The Series B round of financing was led by Eventide Asset Management. Cambridge, MA-based Goldfinch is taking a big data approach to kidney disease drug discovery … Continue reading “Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later”
FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to as “NASH.” New York-based Intercept (NASDAQ: [[ticker:ICPT]]) said Monday that the agency’s complete response letter for obeticholic acid (OCA) stated that its review found that the investigational NASH drug’s benefit “remains uncertain” and does … Continue reading “FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data”
Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More
Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace. Once considered all but shuttered, the IPO market again saw an active week between new public debuts and more companies joining the queue. Indeed, … Continue reading “Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More”
CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy
CSL Behring is joining the chase for a genetic treatment for hemophilia by acquiring a uniQure gene therapy that’s already in late-stage testing. King of Prussia, PA-based CSL Behring is paying $450 million up front to acquire the uniQure (NASDAQ: [[ticker:QURE]]) asset, etranacogene dezaparvovec (“EtranaDez” for short), the companies announced late Wednesday. Netherlands-based uniQure will … Continue reading “CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy”
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins. Now the Cambridge, MA, biotech is looking to tap the public markets to bulk up company coffers and get its two lead drug candidates into mid-stage clinical trials as potential … Continue reading “Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs”
La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War
It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical. San Diego-based La Jolla (NASDAQ: [[ticker:LJPC]]) has pledged to pay Tetraphase shareholders $43 million in cash now … Continue reading “La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War”
Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds
Tiny, naturally occurring particles called exosomes shuffle molecular payloads between cells, facilitating intercellular communication. Codiak Biosciences’ focus is using those nanoparticles to more safely deliver a range of medicines to specific cell types. Now the Cambridge, MA-based biotech has teamed up with neuromuscular disease drug developer Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) to explore using its engineered … Continue reading “Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds”
Diversity & Inclusion Events Have Halted. Our Conversations Shouldn’t.
If the state of current events has shown us one thing, it’s that inclusion matters. Inclusivity is more important than ever. Whether you are black, white, gay, or straight, the time for conversations about inclusion is now. If you’re a small or medium-sized biotech company, you may think you don’t have a place in the … Continue reading “Diversity & Inclusion Events Have Halted. Our Conversations Shouldn’t.”
Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better
Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy approach has saved countless lives and turned drugs from Merck and Bristol Myers Squibb into blockbuster products. But what if a single drug could block checkpoint proteins while simultaneously sparking an anti-tumor response? That’s … Continue reading “Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better”
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire sector. Royalty Pharma (NASDAQ: [[ticker:RPRX]]) acquires the royalty rights for drugs. Most of those royalties are for products that are already approved, but the … Continue reading “Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More”
In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo
Ten years ago Mark Smith was at MIT doing basic research into the microbiome. Now, as CEO of Finch Therapeutics Group, Smith has hard data to back up his company’s thesis that using “good” bacteria as a therapeutic can best a placebo when it comes to at least one condition: a recurrent C. difficile infection. … Continue reading “In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo”
Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies. Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire Series A funding from a sole source: Nan Fung Life Sciences, a subsidiary of … Continue reading “Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs”
Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies
The cancer cell therapies available today are made by tweaking a patient’s own immune cells to better recognize and fight the disease. Orca Bio is developing what it says is the next generation of cell therapy: custom preparations made without modifying cells or genes. Orca is already testing its technology in humans, though it has … Continue reading “Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies”
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing. The San Diego-based company says it will use the money to accelerate its antibody programs, including asking the FDA for the green light to move its lead drug candidate … Continue reading “Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer”
C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic
C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to start human testing. The Watertown, MA-based firm is among a number of companies competing in the popular protein degradation space, in which drug developers … Continue reading “C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic”
Kaleido Bio CEO Lawton Resigns; Company Plans Search for Successor
Kaleido Biosciences (NASDAQ: [[ticker:KLDO]]) president and CEO Alison Lawton stepped down on Tuesday to “attend to an unexpected family health matter,” the microbiome therapies developer said. Lawton joined Kaledio in December 2017 as president and chief operating officer. She was promoted to chief executive in August 2018. The Lexington, MA-based biotech, a Flagship Pioneering spinout, … Continue reading “Kaleido Bio CEO Lawton Resigns; Company Plans Search for Successor”
GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance
GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug class through a research alliance with Ideaya Biosciences that spans three of the biotech’s programs, all slated to reach clinical trials in the next three years. According to deal terms announced … Continue reading “GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance”
Akili Interactive’s Video Game for ADHD Gets the FDA All Clear
The newest attention deficit hyperactivity disorder (ADHD) treatment comes with instructions unlike any other therapy: Press “PLAY.” Akili Interactive was awarded FDA clearance on Monday for EndeavorRx, a “digital therapeutic” developed to treat ADHD through a video game experience. The regulatory decision makes the Boston company’s product the first prescription therapy that comes in the … Continue reading “Akili Interactive’s Video Game for ADHD Gets the FDA All Clear”
FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19
The FDA on Monday revoked its emergency authorization permitting use of the antimalarial drugs hydroxychloroquine and chloroquine to treat the novel coronavirus, citing a lack of evidence of their efficacy. In late March the agency authorized the drugs, which President Donald Trump touts often as a potential treatment, for patients who were hospitalized with COVID-19 … Continue reading “FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19”
GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track
[Corrected 6/17/20, 1:48 pm PT. See below.] GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line ovarian cancer indication for Zejula (niraparib) in April. The belantamab mafodotin and dostarlimab approvals also anticipated this year will give GSK its first … Continue reading “GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track”
Moderna’s Almarsson Jumps To Lyndra for Chief Technology Officer Post
Lyndra Therapeutics has appointed Örn Almarsson to serve as its chief technology officer. Almarsson joins Watertown, MA-based Lyndra from Moderna (NASDAQ: [[ticker:MRNA]]), where he was head of delivery sciences. He was previously vice president of pharmaceutical R&D at Alkermes (NASDAQ: [[ticker:ALKS]]). Lyndra has reached clinical trials testing a drug delivery technology that turn daily pills … Continue reading “Moderna’s Almarsson Jumps To Lyndra for Chief Technology Officer Post”
Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More
At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the … Continue reading “Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More”
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Diabetes drug giant Novo Nordisk has reached a $725 million deal to acquire Corvidia Therapeutics, a clinical-stage biotech developing treatments for disorders affecting the heart and the kidneys. The upfront payment due to Corvidia shareholders is cash. According to the terms of the agreement, Denmark-based Novo Nordisk (NASDAQ: [[ticker:NVO]]) could be on the hook for … Continue reading “Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia”
Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test. The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: [[ticker:MRNA]]) announced Thursday. Those patients will be randomly assigned to receive either … Continue reading “Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine”
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Verve Therapeutics aims to use gene editing to address heart attacks by targeting the liver, not the heart. And it wants to make its edits inside the patient. The startup’s approach raises a lot of questions. Verve has some answers now, and it has raised $63 million to learn more. The new financing announced Thursday … Continue reading “Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes”
Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Melinta Therapeutics and Tetraphase Pharmaceuticals, two antibiotics companies that have struggled separately, will now see if they have better luck together. Morristown, NJ-based Melinta has reached a deal to acquire Tetraphase (NASDAQ: [[ticker:TTPH]]) for $39 million in cash up front. Tetraphase shareholders could earn up to $16 million more if the Watertown, MA-based biotech’s sole … Continue reading “Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition”
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
When fluid builds up in the brain faster than the body can absorb it, pressure builds sparking what’s called hydrocephalus. Surgery can address this condition, but the decades-old approach to relieving the cranial pressure caused by the fluid is susceptible to failure, says Dan Levangie, CEO and president of CereVasc. Levangie’s medical device startup aims … Continue reading “CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain””
Iteos Therapeutics Taps Sarepta’s Gall as Chief Financial Officer
Cancer drug developer Iteos Therapeutics announced Tuesday that it appointed Matthew Gall as its chief financial officer. Gall was most recently senior vice president of corporate development and treasurer at Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]). His previous experience includes roles at Celgene and Gilead Sciences (NASDAQ: [[ticker:GILD]]). Iteos, a Belgium-based firm with US headquarters in Cambridge, … Continue reading “Iteos Therapeutics Taps Sarepta’s Gall as Chief Financial Officer”
Sarepta Eyes Key Test for Gene Therapy in Rare Muscular Dystrophy
The $165 million bet that Sarepta Therapeutics placed on the gene therapy programs of Myonexus Therapeutics is starting to pay off with more early but encouraging clinical data from the deal’s most advanced program—a potential treatment for a type of limb-girdle muscular dystrophy. Currently no available treatments exist for any of the many subtypes of … Continue reading “Sarepta Eyes Key Test for Gene Therapy in Rare Muscular Dystrophy”
Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic
Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these problems and it’s planning an IPO to finance the first tests of its approach in humans. In paperwork filed with regulators late Friday, Boston-based Akouos set a preliminary … Continue reading “Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic”
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect the broad spectrum of patients that drug makers aim to treat. Racial disparities are … Continue reading “Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More”
Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs
Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are creating new medicines. Atlas revealed Friday that it closed its 12th fund after raising $400 million, a total that pushes the amount the company has … Continue reading “Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs”
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline
Cullinan Oncology emerged nearly three years ago with an approach to cancer drugs its founders said would improve the odds of success. Now it has a pipeline of seven compounds and a fresh $98.5 million to advance all of them. The new cash announced Thursday is a Series B round of funding that added the … Continue reading “Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline”